Dashboard
Manage Tickers

TRVI


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

trevi-therapeutics-announced-two-accepted-abstracts-for-presentation-at-the-chest-2025-annual-meeting-in-chicago-oct-1922-2025
Trevi Therapeutics Announced Two Accepted ...
10/08/2025 11:41:00

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
10/03/2025 21:05:59

Core News & Articles
10 Health Care Stocks Whale Activity In To...
09/09/2025 17:35:29

trevi-therapeutics-option-alert-sep-19-7-calls-sweep-60-near-the-ask-951--1249-vs-11-oi-ref809
Trevi Therapeutics Option Alert: Sep 19 $7...
08/27/2025 15:49:13

this-adient-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday
This Adient Analyst Begins Coverage On A B...
08/21/2025 12:32:13

morgan-stanley-initiates-coverage-on-trevi-therapeutics-with-overweight-rating-announces-price-target-of-18
Morgan Stanley Initiates Coverage On Trevi...
08/21/2025 11:16:06

Morgan Stanley analyst Judah Frommer initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Overweight rating and ann...

lisa-delfini-to-resign-as-cfo-of-trevi-therapeutics-on-aug-22--jennifer-l-good-to-serve-as-interim-principal-financial-officer
Lisa Delfini To Resign As CFO Of Trevi The...
08/20/2025 20:35:29

-SEC Filing

raymond-james-maintains-strong-buy-on-trevi-therapeutics-lowers-price-target-to-27
Raymond James Maintains Strong Buy on Trev...
08/08/2025 16:16:28

Raymond James analyst Ryan Deschner maintains Trevi Therapeutics (NASDAQ:TRVI) with a Strong Buy and lowers the price target...

needham-maintains-buy-on-trevi-therapeutics-lowers-price-target-to-22
Needham Maintains Buy on Trevi Therapeutic...
08/08/2025 11:32:25

Needham analyst Serge Belanger maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and lowers the price target from $24 to...

trevi-therapeutics-q2-eps-009-beats-010-estimate
Trevi Therapeutics Q2 EPS $(0.09) Beats $(...
08/07/2025 20:06:27

Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(...

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

cantor-fitzgerald-initiates-coverage-on-trevi-therapeutics-with-overweight-rating-announces-price-target-of-25
Cantor Fitzgerald Initiates Coverage On Tr...
07/01/2025 13:44:56

Cantor Fitzgerald analyst Josh Schimmer initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Overweight rating and ...

reported-earlier-trevi-therapeutics-prices-100m-public-offering-of-174m-common-shares-at-575share
Reported Earlier, Trevi Therapeutics Price...
06/04/2025 05:57:31

dow-gains-over-100-points-us-job-openings-increase-in-april
Dow Gains Over 100 Points; US Job Openings...
06/03/2025 16:16:27

trevi-therapeutics-launches-100m-public-offering-of-common-stock-to-support-development-of-haduvio-for-chronic-cough-in-ipf-and-rcc
Trevi Therapeutics Launches $100M Public O...
06/02/2025 20:02:36

Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduv...

trevi-therapeutics-showcases-drug-that-cuts-cough-frequency-in-lung-disease-patients
Trevi Therapeutics Showcases Drug That Cut...
06/02/2025 17:42:49

Trevi's Haduvio met its primary endpoint in a Phase 2b trial for IPF-related chronic cough, with statistically significant ...

d-boral-capital-maintains-buy-on-trevi-therapeutics-maintains-21-price-target
D. Boral Capital Maintains Buy on Trevi Th...
06/02/2025 11:54:26

D. Boral Capital analyst Jason Kolbert maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $21 price target.

trevis-cough-drug-haduvio-shows-results-in-ipf-patients-cutting-coughs-by-over-60
Trevi's Cough Drug Haduvio Shows Results i...
06/02/2025 11:12:02

Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduv...

hc-wainwright--co-initiates-coverage-on-trevi-therapeutics-with-buy-rating-announces-price-target-of-21
HC Wainwright & Co. Initiates Coverage On ...
05/28/2025 10:39:57

HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Buy rating and ...

needham-reiterates-buy-on-trevi-therapeutics-maintains-24-price-target
Needham Reiterates Buy on Trevi Therapeuti...
05/20/2025 12:04:17

Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $24 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION